Abstract
This is the first study showing the impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in Latin America; a significant (63.5%) reduction in hospitalization was observed during the first 6 years after starting vaccination. A 90% reduction of pneumococcal conjugate vaccines 7/13 serotypes was observed (P < 0.0001). After vaccination, all strains were penicillin susceptible. Mortality had a reduction of 71%.
MeSH terms
-
Heptavalent Pneumococcal Conjugate Vaccine* / administration & dosage
-
Heptavalent Pneumococcal Conjugate Vaccine* / therapeutic use
-
Hospitalization / statistics & numerical data*
-
Hospitals, Pediatric
-
Humans
-
Immunization / statistics & numerical data*
-
Infant
-
Meningitis, Pneumococcal* / epidemiology
-
Meningitis, Pneumococcal* / prevention & control
-
Pneumococcal Vaccines* / administration & dosage
-
Pneumococcal Vaccines* / therapeutic use
-
Streptococcus pneumoniae
-
Uruguay / epidemiology
Substances
-
13-valent pneumococcal vaccine
-
Heptavalent Pneumococcal Conjugate Vaccine
-
Pneumococcal Vaccines